

K-H Peiffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4194919/publications.pdf>

Version: 2024-02-01

27
papers

400
citations

840119

11
h-index

794141

19
g-index

28
all docs

28
docs citations

28
times ranked

760
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?. <i>Gut</i> , 2022, 71, 1036-1038.	6.1	13
2	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	3.0	50
3	A 55-Year-Old Man with Recurrent Gastrointestinal Bleeding Due to Stricture of the Portal Vein Anastomotic Site 12 Years After Combined Pancreas and Kidney Transplantation.. <i>American Journal of Case Reports</i> , 2022, 23, e936148.	0.3	2
4	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
5	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1â€³ Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
6	Not uncommon: HBV genotype G coâ€infections among healthy European HBV carriers with genotype A and E infection. <i>Liver International</i> , 2021, 41, 1278-1289.	1.9	3
7	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	6
8	The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles. <i>Cells</i> , 2020, 9, 1898.	1.8	5
9	Resistanceâ€associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
10	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistanceâ€associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	1.9	2
11	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , 2020, 5, .	2.3	2
12	Formation of semiâ€enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 940-954.	1.9	9
13	Editorial: HBVâ€the naked truth? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 964-965.	1.9	0
14	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	5
15	Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy340.	0.4	11
16	Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 114-123.	1.9	37
17	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 524-530.	0.8	7
18	Impact of <sc>HBV</sc> genotype and mutations on <sc>HBV DNA</sc> and <sc>qHBsA</sc>g levels in patients with <sc>HB</sc>eAgâ€negative chronic <sc>HBV</sc> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1523-1535.	1.9	33

#	ARTICLE	IF	CITATIONS
19	Letter: impact of HBV genotypes and PC/BCP mutations on serum HBsAg levels in Chinese HBeAg negative patients – Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 238-239.	1.9	3
20	Editorial: HBsAg serum levels in HBeAg-negative chronic HBV infection – is it a matter of genotype? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 103-104.	1.9	0
21	No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Alimentary Pharmacology and Therapeutics, 2017, 46, 432-439.	1.9	39
22	Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes. Virology, 2017, 502, 1-12.	1.1	22
23	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology, 2016, 63, 63-73.	3.6	50
24	European RAVS Database: Frequency and Characteristics of RAVS in Treatment-Naïve and DAA-Experienced Patients. Journal of Hepatology, 2016, 64, S139.	1.8	12
25	Reply. Hepatology, 2016, 64, 1378-1379.	3.6	0
26	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731.	1.1	5
27	Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. Journal of Hepatology, 2015, 62, 791-798.	1.8	33